| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528169 | Clinical Therapeutics | 2018 | 10 Pages |
Abstract
The moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide test regimen yielded higher success and lower recurrence rates than the currently recommended isoniazid, rifampicin, and streptomycin regimen, but the rate of adverse effects was higher. ClinicalTrials.gov identifier: NCT02331823.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Liping MD, Xiaohong MD, Limei MD, Kaijin MD, Jianjun MD, Li MD, Yong MD, Ji MD, Wenyu MD, Juan PhD, Lihua MD, Shouyong MD, Xiangao MD, Zhong MD, Shenghui MD, Lin MD, Yu MD, Weiguo MD, Heping MD,